drugset / Trial / NCT04505722

A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants

NCT04505722

Phase 3 Completed 44325 enrolled Janssen Vaccines & Prevention B.V.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly confirmed moderate to severe/critical COVID-19, as compared to placebo, in adult participants.

Timeline

Start
2020-09-07
Primary completion
2023-03-31
Completion
2023-03-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.COV2.S Vaccine 5e+10 unknown Intramuscular

Indications

No indication recorded.